The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clı́nicas de Porto Alegre

Piltcher, Otávio Bejzman; Teixeira, Vanessa Niemiec; Oliveira, Mônica Maria Celestina de; Scattolin, Isabella; Piltcher, Simão Levin

doi:10.1016/s0165-5876(03)00135-6

Cited by 16 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a prevalence of 56% (45 of 81 ears) for SNHL in CF ears with a history of IV-AG (+/− vancomycin) treatments. The prevalence of SNHL in this study is slightly higher than reported in previous studies by others that ranged between 0–47% (2, 9, 11–14, 20, 21). The majority of prior studies tested pediatric patients 0 to18 years of age, and their methodological approach for classifying hearing loss was limited to a standard hearing test range of 0.25–8.0 kHz.…”

Section: Discussioncontrasting

confidence: 80%

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Garinis

Cross

Srikanth

et al. 2017

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Background Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status. Methods Hearing thresholds were measured from 0.25 to 16.0 kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤25 dB HL for all frequency bands) or hearing loss (>25 dB HL for any frequency band in either ear). Participants were also characterized by their cumulative intravenous (IV)-AG (with or without vancomycin) exposure by comparing the total number of lifetime cumulative IV doses to a method that additionally accounts for the total number of doses per day (weighted method) per course of treatment. Results Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. Conclusions Cumulative IV antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.

show abstract

Section: Discussioncontrasting

confidence: 80%

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Garinis

Cross

Srikanth

et al. 2017

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…Tobramycin- and aminoglycoside-induced ototoxicity reports range from nearly absent to approximately 35% of cystic fibrosis patients (Mulheran et al 2001, 2006; Piltcher et al 2003; Cheng et al 2009; Guy et al 2010; Martins et al 2010; Scheenstra et al 2010; Al-Malky et al 2011; Hennig et al 2014) with an increased risk of aminoglycoside-induced hearing loss with repeated and higher cumulative doses. The majority of adolescent and adult cystic fibrosis patients are colonized with Pseudomonas aeruginosa ( P. aeruginosa) (Cystic Fibrosis Foundation Registry 2011).…”

Section: Discussionmentioning

confidence: 99%

d -Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models

Fox

Cooper

Speil

et al. 2016

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Background Tobramycin is a critical cystic fibrosis treatment however it causes ototoxicity. This study tested D-methionine protection from tobramycin-induced ototoxicity and potential antimicrobial interference. Methods Auditory brainstem responses (ABR) and outer hair cell (OHC) quantifications measured protection in guinea pigs treated with tobramycin and a range of D-methionine doses. In vitro antimicrobial interference studies tested inhibition and post antibiotic effect assays. In vivo antimicrobial interference studies tested normal and neutropenic E. coli murine survival and intraperitoneal lavage bacterial counts. Results D-methionine conferred significant ABR threshold shift reductions. OHC protection was less robust but significant at 20 kHz in the 420 mg/kg/day group. In vitro studies did not detect D-methionine-induced antimicrobial interference. In vivo studies did not detect D-methionine-induced interference in normal or neutropenic mice. Conclusions D-methionine protects from tobramycin-induced ototoxicity without antimicrobial interference. The study results suggest D-met as a potential otoprotectant from clinical tobramycin use in cystic fibrosis patients.

show abstract

“…Of these initial 75 studies, 63 studies did not meet inclusion criteria and were excluded. A total of 12 articles were included in the final review (Table ) . Three of the 12 articles also studied adult CF patients.…”

Section: Resultsmentioning

confidence: 99%

“…All studies were carried out at single institutions except for Mulheran et al, which was a multicenter study. Eight of 12 studies (66.7%) utilized statistical analysis . A comprehensive overview of the studies is presented in Table .…”

Section: Resultsmentioning

confidence: 99%

The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review

et al. 2015

View full text Add to dashboard Cite

show abstract

The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clı́nicas de Porto Alegre

Cited by 16 publications

References 14 publications

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

d -Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models

The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review

Contact Info

Product

Resources

About